ANNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Annexon, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.01+0.60 (+17.60%)
Close on Oct 19, 2026
- Market cap
- $806.02M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -52.0% | -81.9% | |
| Return on assets | – | -31.2% | -65.9% | |
| Current ratio | – | 33.33 | 5.68 | |
| Diluted shares | – | 17M | 155M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Annexon generated $647.92M from operations and spent $8.53M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$647.92M
Used
$8.53M
Capital expenditure$8.53M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$206.69M
- Cash generatingOperating cash flow above zero-$186.36M
- Return on assets improvedROA up on the prior year-46.4% → -59.0%
- Earnings backed by cashOperating cash flow above net income-$186.36M vs -$206.69M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose10.37 → 5.68
- No dilutionShare count did not rise137M → 155M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –